Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 112,611

Document Document Title
WO/2016/111843A1
Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferriti...  
WO/2016/111357A1
The present invention is directed to the compound (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9- tetrahydrospiro[ß-carboline-4,1'-cyclopropane] represented by the formula. This compound, when compared to conventionally-kno...  
WO/2016/110334A1
The invention relates to the pharmaceutical or non-pharmaceutical use of an effective amount of spirulina and/or of an extract/extracts of spirulina for improving the bioavailability of orally administered curcumin in humans or animals. ...  
WO/2016/112205A1
Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treat...  
WO/2016/112382A2
The presently disclosed subject matter provides methods for treating and diagnosing neurological diseases or disorders using intranasal administration of glutamate carboxypeptidase II (GCP-II) inhibitors in a subject. Methods for imaging...  
WO/2016/110541A1
The present invention relates to selective Histone deacetylase 6 (HDAC6) inhibitors and compositions containing the same. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cell proliferati...  
WO/2016/111377A1
The medicinal composition and cosmetic according to the present disclosure each comprise an iPS cell culture supernatant that is obtained by culturing iPS cells. The present disclosure also provides: a method for producing the aforesaid ...  
WO/2016/111378A1
The composition for treating a neurodegenerative disease according to the present disclosure comprises an iPS cell culture supernatant that is obtained by culturing iPS cells. The present disclosure also provides: a method for producing ...  
WO/2016/111381A1
Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A2A receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson's disease, sleep disorder, ...  
WO/2016/110822A1
The invention relates to a novel creatine derivative, the carboxylic biacyl creatine derivative of formula (I) and pharmaceutically acceptable salts thereof, methods of synthesis and the use thereof in the treatment of pathologies due to...  
WO/2016/110768A1
Pharmaceutical composition for the treatment of proteinopathies comprising products which are able to stimulate growth or inhibition of at least one of Odoribacter, Oscillospira, Dehalobacterium, Alistipes, Parabacteroides, Lactobacillus...  
WO/2016/109880A1
The invention provides lipid A mimics in which one or both of the sugar residues of a natural lipid A disaccharide backbone has been replaced with an aromatic group. These lipid A mimics may further differ from a natural lipid A molecule...  
WO/2016/110160A1
Provided are methods of treating brain ischemia or hypoxia by using an inhibitor of cysteine-glutamate transporter. The inhibitor includes sorafenib and a derivative thereof, regorafenib, erastin and sulfasalazine. The inhibitor can effe...  
WO/2016/112263A1
There is described a pharmaceutical combination comprising oxybutynin or a pharmaceutically acceptable addition salt thereof, in a transdermal therapeutic system, and an acetylcholinesterase inhibitor, useful for safely treating hypochol...  
WO/2016/109531A1
This invention generally relates to an ophthalmic solution comprising cannabinoids for the treatment of glaucoma. Also disclosed is an ophthalmic solution comprising cannabinoids for symptomatic relief of conjunctival inflammation. Canna...  
WO/2016/107227A1
Disclosed are a pyrrole amide compound as represented in formula I, polymorphs thereof, or pharmaceutically acceptable salts, hydrates, or solvate compounds. The present invention has good deacetylase inhibitory activity. Additionally, t...  
WO/2016/107540A1
Disclosed are a Chinese medicinal composition for preventing or treating cardiovascular and cerebrovascular diseases and/or dementia, and a preparation method and use thereof. The composition is prepared from the following medical raw ma...  
WO/2016/109624A1
Novel treatment methods of controlling cell hyperexcitability occurring in a neurological disease or disorder associated with epileptogenesis or cardiac disorder are disclosed herein. Novel pharmaceutical compositions comprising adenosin...  
WO/2016/107579A1
The present application provides a preparation and application of flavonol as a brain-targeting synergist. The flavonol is selected from kaempferide, rutin, troxerutin, myricetin, hesperidin and derivatives thereof. The flavonol is capab...  
WO/2016/107544A1
An intermediate compound shown in formula I for preparing a pyrrole amide compound. The pyrrole amide compound has a good histone deacetylase inhibitory activity. The specific definition of the groups in formula I is shown in the descrip...  
WO/2016/107865A1
This invention relates to compounds of formula (I), their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevent...  
WO/2016/107541A1
Disclosed are a pyrrole amide compound as represented in formula I, or pharmaceutically acceptable salts, polymorphs, hydrates, or solvate compounds. R1 is chosen from hydrogen, hydroxyl, the cyano group, halogen, carboxyl, etc. R2 and R...  
WO/2016/107850A1
The invention relates to a method for obtaining a superoxide dismutase (SOD)-concentrated protein extract having a specific activity of at least 700 UI/mg protein, said method comprising a single step of extraction from a plant selected ...  
WO/2016/106760A1
Disclosed are a trifluoroacethydrazide compound as well as preparation and application thereof. The compound has a structure represented by general formula (I). The compound has multiple mechanisms of action, comprising inhibition of glu...  
WO/2016/109480A1
The invention relates to pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one and imidazo[5,1-f][1,2,4]triazin-4(3H)-one derivatives as inhibitors of the ubiquitin-specific protease 7 (USP7) useful in the treatment of cancers, neurodegenerative diseas...  
WO/2016/106626A1
A Bruton's Tyrosine Kinase (Btk) inhibitor compounds of Formula (I), or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use of Btk inhibito...  
WO/2016/106625A1
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use ...  
WO/2016/102706A1
The invention relates to a compound of general formula (I) (in configuration Z or E) and to pro-pheromonal compositions and formulations comprising said compound, in addition to the uses thereof for soothing purposes for non-human mammal...  
WO/2016/103450A1
The present invention addresses the problem of providing an inhibitor which has excellent inhibitory activity on a p21-activated kinase. The present invention, which has solved the above-mentioned problem, is a p21-activated kinase 1 inh...  
WO/2016/103262A2
The present invention provides solid crystalline forms of apomorphine free base or a hydrate, solvate, or co-crystals thereof. Such crystalline forms may be advantageous over amorphous forms of apomorphine, e.g., amorphous salt forms suc...  
WO/2016/101553A1
The present invention relates to a PI3K kinase inhibitor, comprising a compound of a formula I or pharmaceutically acceptable salts, solvate, ester, acid, metabolite, or a prodrug thereof, Y, W, Z, R1, R2, R3, and R4 being defined in the...  
WO/2016/104434A1
To provide a heterocyclic compound having antagonistic activity on NMDA receptors having the NR2B subunit, and which is useful as an agent for treating or preventing major depression, bipolar disorder, migraine, pain, symptoms peripheral...  
WO/2016/103133A1
The invention relates to novel soothing compositions for animals, particularly for cats. It specifically relates to soothing compositions for non-human mammals, comprising between 1% and 50% w/w of at least one fatty acid comprising betw...  
WO/2016/101898A1
The present invention relates to 3-[(benzo[d][1,3]dioxolane-4-yl)-oxy]-3-arylaniline type compounds of Formula I or pharmaceutical acceptable salts thereof and applications thereof. The compound may be used to prepare antidepressants.  
WO/2016/106284A2
The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and ...  
WO/2016/102463A1
The invention relates to a product or pharmaceutical composition comprising remifentanil and propofol, or the pharmaceutically acceptable salts thereof, as a combined preparation for simultaneous use in inducing and maintaining general a...  
WO/2016/106133A1
Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.  
WO/2016/103956A1
The purpose of the present invention is to provide a ropinirole-containing preparation for transdermal administration and a pramipexole-containing preparation for transdermal administration, which have good extended release properties. T...  
WO/2016/105485A3
The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.  
WO/2016/101969A1
The present inventions relates to a solid pharmaceutical dosage form comprising Levodopa/Entacapone/Carbidopa, or pharmaceutically acceptable salts or hydrates thereof, characterized in that the active agents are stabilized with the use ...  
WO/2016/103223A1
In one aspect, the invention presents a method of treating Friedreich's ataxia (FRDA) by administering a therapeutically effective amount of an Src inhibitor.  
WO/2016/101432A1
Disclosed in the present invention is a crystal form I of Canagliflozin, and an X-ray powder diffraction spectrum of the crystal form I has characteristic diffraction peaks when 2θ is at the positions of 4.4 ± 0.2°, 8.4 ± 0.2°, 16.8...  
WO/2016/103260A1
The present invention relates to complexes of nocardamine (desferrioxamine E) with at least one metal, specifically with Zn2+ or Ga3+ or silver or gold or any combinations thereof. The invention further provides procedures for the prepar...  
WO/2016/102664A1
The present invention provides for a double stranded RNA comprising a first RNA sequence and a second RNA sequence wherein the first and second RNA sequence are substantially complementary, wherein the first RNA sequence has a sequence l...  
WO/2016/101807A1
A solid pharmaceutical composition comprising topiramate and preparation method therefor. The pharmaceutical composition comprises: topiramate, cellulose derivatives, lipids and optional excipients, where the weight ratio of topiramate t...  
WO/2016/103262A3
The present invention provides solid crystalline forms of apomorphine free base or a hydrate, solvate, or co-crystals thereof. Such crystalline forms may be advantageous over amorphous forms of apomorphine, e.g., amorphous salt forms suc...  
WO/2016/101118A1
An amidoethyl azole compounds are provided as antagonists of orexin receptors. The compounds may be used for treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.  
WO/2016/099056A3
The present invention relates to a pharmaceutical composition containing a Poria cocos bark extract as an effective ingredient for preventing or treating neurodegenerative disorders, and to a food composition for preventing or improving ...  
WO/2016/095650A1
Disclosed are an A-type polymorphic substance of yonkenafil hydrochloride, a preparation method therefor, and a composition and use thereof. A powder diffraction pattern of the A-type polymorphic substance of yonkenafil hydrochloride com...  
WO/2016/100385A3
The disclosure provides compounds, compositions, and methods for promoting motor neuron survival, and for treating or preventing neurodegenerative disorders, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). ...  

Matches 201 - 250 out of 112,611